Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Nevro

Evaluate

Thumbnail
September 06, 2022

Medtech takes on pain

Attempts to treat pain with non-opioid drugs have ended in repeated failures – but device makers have met with greater success.

Thumbnail
January 11, 2022

Diabetes device makers lead the smaller medtechs

Insulin pumps and glucose sensors flew off the shelves, whereas liquid biopsy developers both soared and sank.

Article image
Vantage logo
January 08, 2020

2019 was all about execution for smaller device makers

New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.

Article image
Vantage logo
January 14, 2019

Led by Tandem, small-cap medtechs pump up the value in 2018

The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.

Article image
Vantage logo
November 19, 2018

Neurostimulation sham scuppers Mainstay

Mainstay Medical still hopes for US approval of its Reactiv8 device for chronic back pain despite trial failure.

Vantage logo
October 10, 2017

Neurostimulation approvals show therapy’s potential

Article image
Vantage logo
August 02, 2017

Lack of takeovers sees medtech hiring staff again

Intuitive Surgical is the winner in terms of sales per employee, despite increasing its headcount 17%.

Vantage logo
September 01, 2016

Medtech mergers still the driving force behind jobs changes

Vantage logo
April 21, 2016

Interview – $29m for prototype-stage G-Therapeutics

Vantage logo
January 14, 2016

Sector trends dictate smaller medtechs’ share performance

Vantage logo
May 12, 2015

Nevro snags best-in-class label for spine stimulator

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up